ALAN JENSEN: Open Payments
NPI 1053495614 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$362 in 13 payments from 8 companies in 2025. Trend: 2023 $490 · 2024 $470 · 2025 $362
Food & beverage: $362
| Company | Payments | Amount |
|---|---|---|
| Avadel CNS Pharmaceuticals, LLC | 3 | $137 |
| ABBVIE INC. | 3 | $70 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $40 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Almatica Pharma LLC | 1 | $24 |
| Antares Pharma, Inc. | 1 | $23 |
| Novo Nordisk Inc | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $20 |
Products named: LUMRYZ, VRAYLAR, CAPLYTA, Auvelity, LOREEV XR, LINZESS, XYOSTED, Ozempic.
Industry payments across NE — which companies pay providers there.
